Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. Winter 2009;15(1):65-75.
doi: 10.1111/j.1755-5949.2008.00065.x.

Cannabidiol: A Promising Drug for Neurodegenerative Disorders?

Affiliations
Free PMC article
Review

Cannabidiol: A Promising Drug for Neurodegenerative Disorders?

Teresa Iuvone et al. CNS Neurosci Ther. .
Free PMC article

Abstract

Neurodegenerative diseases represent, nowadays, one of the main causes of death in the industrialized country. They are characterized by a loss of neurons in particular regions of the nervous system. It is believed that this nerve cell loss underlies the subsequent decline in cognitive and motor function that patients experience in these diseases. A range of mutant genes and environmental toxins have been implicated in the cause of neurodegenerative disorders but the mechanism remains largely unknown. At present, inflammation, a common denominator among the diverse list of neurodegenerative diseases, has been implicated as a critical mechanism that is responsible for the progressive nature of neurodegeneration. Since, at present, there are few therapies for the wide range of neurodegenerative diseases, scientists are still in search of new therapeutic approaches to the problem. An early contribution of neuroprotective and antiinflammatory strategies for these disorders seems particularly desirable because isolated treatments cannot be effective. In this contest, marijuana derivatives have attracted special interest, although these compounds have always raised several practical and ethical problems for their potential abuse. Nevertheless, among Cannabis compounds, cannabidiol (CBD), which lacks any unwanted psychotropic effect, may represent a very promising agent with the highest prospect for therapeutic use.

Conflict of interest statement

All authors disclose any potential conflicts of interest, including all relevant financial interests (e.g. employment, significant share ownership, patent rights, consultancy, research funding) in any company or institution that might benefit from the publication.

Similar articles

See all similar articles

Cited by 49 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback